Editorial Volume 11, Issue 23 pp 10791—10792
PCSK9 inhibition in high-risk patients
- 1 Department of Cardiology Leiden University Medical Center, The Netherlands
- 2 Department of Gerontology and Geriatrics Leiden University Medical Center, The Netherlands
- 3 Institute for Evidence-based Medicine in Old Age (IEMO), Leiden, the Netherlands
received: October 31, 2019 ; published: December 11, 2019 ;https://doi.org/10.18632/aging.102621
How to Cite
Copyright © 2019 Zijlstra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ACS: acute coronary syndrome; CABG: coronary artery bypass grafting; CeVD: cerebrovascular disease; CI: confidence interval; CVD: cardiovascular disease; HR: hazard ratio; LDL-C: low-density lipoprotein cholesterol; MACE: major adverse cardiovascular events; PCSK9: proprotein convertase subtilisin–kexin type 9.